Source: International Congress 2019 – Biology and prognosis of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
D. Groves (stevenage, United Kingdom), N. Noor Al-Nuaimi (London, United Kingdom), B. Ganeshan (London, United Kingdom), T. Win (stevenage, United Kingdom). Maximum Standard Unit Value (SUVmax) is an indicator for overall survival in lung cancer. 3043

Member's Comments

No comment yet.

Related content which might interest you: Preoperative predictive value of 18FDG CT/PET tumor metabolic parameters & SUV lymh nodes/tumor ratio in NSCLC Source: International Congress 2015 – Risk assessment and prevention of complications in thoracic surgery Year: 2015 Role of mean sUV and metabolic tumor volume by PET/CT for determination of mean survival time in patients with non-small cell lung cancer Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014 Oncogenic drivers (OD) and matched targeted agents (TA): Impact on overall survival in patients with lung adenocarcinoma (LA)? Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Significance of imaging-related and other factors as predictors of survival time in non small cell lung cancer Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer Year: 2013 Accuracy of the calculated estimated postoperative pulmonary function (CEPPF) in lung cancer patients Source: Annual Congress 2007 - Prognosis and diagnosis of thoracic malignancies Year: 2007 Preoperative FDG uptake on PET/CT predicts disease recurrence and survival in early stage non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Clinical aspects of lung cancer Year: 2016 Correlation between standardised uptake value on PET scans, tumour characteristics and survival in resected lung cancer patients Source: Annual Congress 2007 - Prognosis and diagnosis of thoracic malignancies Year: 2007 The prognostic value of the tumor shrinkage rate for progression-free survival in patients with non-small cell lung cancer receiving gefitinib Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 Preoperative cell counts of white blood cell, neutrophil, lymphocyte and neutrophil/lymphocyte ratio as a predictive parameter of survival rate after complete resection for non-small cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Development and validation of a prognostic index for survival in patients with non-small-cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016 Comparing performance and cost of EBUS-TBNA versus other methods for diagnosis and staging of non-small cell lung cancer (NSCLC) Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014 Prediction of postoperative DLCO in lung cancer patients after lobectomy. Comparison between quantitative CT and the anatomic method Source: International Congress 2016 – Surgical strategy for complex diseases Year: 2016 Prognostic factors affecting survival in cases with lung cancer [A lung cancer mapping project in Turkey (LCMPT)] Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 The prognostic impact of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with non-small cell lung cancer Source: International Congress 2016 – Lung cancer and immune cells: friends or foes? Year: 2016 Differences in expression and prognostic values of p16(ink) and VEGF in squamous and adenocarcinoma of the lung Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Long-term survival is linked to serum LDH normalization in SCLC Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Evaluation of predictive and therapeutic value of WSX1/IL27 axis in non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Concurrent chemoradiation in stage III NSCLC: High eligilbility and high rates of overall and progression-free survival with acceptable toxicity Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts Year: 2013 Exercise testing to predict lung cancer surgery outcome: which is better - percentage of predicted VO2 or absolute value? Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004 Should preoperative FDG uptake on PET/CT guide postoperative surveillance in surgical non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016